Stunner: Marc Garnick, one of the principal investigators into the drug Lupron when it was tested and approved by the FDA, responded to the New York Times’ story on the potential dangers of the medical treatment of gender dysphoria. I wrote about the story in a VIP column a couple of weeks ago. The article actually raised the question about the safety of “gender affirming care,” and called into question the claims about how safe and effective the treatments being provided to children really are. It was the first MSM story that opened up the path to mainstream criticism of...